Doxapram as an additive to propofol sedation for endoscopic retrograde cholangiopancreatography: a placebo-controlled, r
- PDF / 867,897 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 32 Downloads / 224 Views
and Other Interventional Techniques
Doxapram as an additive to propofol sedation for endoscopic retrograde cholangiopancreatography: a placebo‑controlled, randomized, double‑blinded study Jarno Jokelainen1,2 · Anna Belozerskikh3 · Harri Mustonen2,4 · Marianne Udd2,4 · Leena Kylänpää2,4 · Outi Lindström2,4 · Maxim Mazanikov3 · R. Pöyhiä2,5 Received: 9 July 2019 / Accepted: 24 December 2019 © The Author(s) 2020
Abstract Background Endoscopic retrograde cholangiopancreatography (ERCP) requires moderate to deep sedation, usually with propofol. Adverse effects of propofol sedation are relatively common, such as respiratory and cardiovascular depression. This study was conducted to determine if doxapram, a respiratory stimulant, could be used to reduce the incidence of respiratory depression. Methods This is a single-center, prospective randomized double-blind study performed in the endoscopy unit of Helsinki University Central Hospital. 56 patients were randomized in a 1:1 ratio to either receive doxapram as an initial 1 mg/kg bolus and an infusion of 1 mg/kg/h (group DOX) or placebo (group P) during propofol sedation for ERCP. Main outcome measures were apneic episodes and hypoxemia ( SpO2
Data Loading...
